Vaccine Effectiveness against Mpox in the United States

Vaccine Effectiveness against Mpox in the United States

To the Editor: Deputy et al. (June 29 issue) 1 report the estimated vaccine effectiveness of JYNNEOS vaccination against mpox in a case–control study. Their estimate of vaccine effectiveness with a single dose is substantially lower than the estimates from previous reports. The definition of the con...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The New England journal of medicine 2023-10, Vol.389 (15), p.1440-1441
Hauptverfasser: Arbel, Ronen, Zucker, Roy, Wolff-Sagy, Yael, Deputy, Nicholas P., Gerhart, Jacqueline L., Feldstein, Leora R.
Format: Artikel
Sprache:eng
Schlagworte:
Conflicts of interest
Disease control
Disease prevention
Effectiveness studies
Estimates
HIV
Human immunodeficiency virus
Humans
Immunization
Infections
Mpox
Mpox (monkeypox)
Prophylaxis
United States
Vaccine Efficacy
Vaccines
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:To the Editor: Deputy et al. (June 29 issue) 1 report the estimated vaccine effectiveness of JYNNEOS vaccination against mpox in a case–control study. Their estimate of vaccine effectiveness with a single dose is substantially lower than the estimates from previous reports. The definition of the control group (patients with an incident diagnosis of human immunodeficiency virus [HIV] infection or a new or refill order for preexposure prophylaxis against HIV infection) may not be representative of the patients who are intended to receive the vaccine against mpox. Indeed, only 309 of 2266 patients with mpox (13.6%) met these criteria. Moreover, the . . .
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMc2309583